Cargando…
Liver and kidney function in patients with Covid‐19 treated with remdesivir
For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver fun...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251044/ https://www.ncbi.nlm.nih.gov/pubmed/33763917 http://dx.doi.org/10.1111/bcp.14831 |
_version_ | 1783717080205361152 |
---|---|
author | van Laar, Sylvia A. de Boer, Mark G. J. Gombert‐Handoko, Kim B. Guchelaar, Henk‐Jan Zwaveling, Juliette |
author_facet | van Laar, Sylvia A. de Boer, Mark G. J. Gombert‐Handoko, Kim B. Guchelaar, Henk‐Jan Zwaveling, Juliette |
author_sort | van Laar, Sylvia A. |
collection | PubMed |
description | For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid‐19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m(2). Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid‐19 if these functions are monitored regularly. A larger patient cohort is warranted to confirm our results. |
format | Online Article Text |
id | pubmed-8251044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82510442021-07-02 Liver and kidney function in patients with Covid‐19 treated with remdesivir van Laar, Sylvia A. de Boer, Mark G. J. Gombert‐Handoko, Kim B. Guchelaar, Henk‐Jan Zwaveling, Juliette Br J Clin Pharmacol Short Reports For the treatment of Covid‐19 patients with remdesivir, poor renal and liver function were both exclusion criteria in randomized clinical trials and contraindication for treatment. Also, nephrotoxicity and hepatotoxicity are reported as adverse events. We retrospectively reviewed renal and liver functions of Covid‐19 103 patients who received remdesivir in the 15 days after treatment initiation. Approximately 20% of the patient population met randomized clinical trial exclusion criteria. In total, 11% of the patients had a decrease in estimated glomerular filtration rate >10 mL/min/1.73m(2). Also, 25 and 35% had increased alanine transaminase and aspartate transaminase levels, respectively. However, serious adverse events were limited. Therefore, based on these preliminary results, contraindications based on kidney and liver function should not be absolute for remdesivir treatment in patients with Covid‐19 if these functions are monitored regularly. A larger patient cohort is warranted to confirm our results. John Wiley and Sons Inc. 2021-05-04 2021-11 /pmc/articles/PMC8251044/ /pubmed/33763917 http://dx.doi.org/10.1111/bcp.14831 Text en © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Short Reports van Laar, Sylvia A. de Boer, Mark G. J. Gombert‐Handoko, Kim B. Guchelaar, Henk‐Jan Zwaveling, Juliette Liver and kidney function in patients with Covid‐19 treated with remdesivir |
title | Liver and kidney function in patients with Covid‐19 treated with remdesivir |
title_full | Liver and kidney function in patients with Covid‐19 treated with remdesivir |
title_fullStr | Liver and kidney function in patients with Covid‐19 treated with remdesivir |
title_full_unstemmed | Liver and kidney function in patients with Covid‐19 treated with remdesivir |
title_short | Liver and kidney function in patients with Covid‐19 treated with remdesivir |
title_sort | liver and kidney function in patients with covid‐19 treated with remdesivir |
topic | Short Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251044/ https://www.ncbi.nlm.nih.gov/pubmed/33763917 http://dx.doi.org/10.1111/bcp.14831 |
work_keys_str_mv | AT vanlaarsylviaa liverandkidneyfunctioninpatientswithcovid19treatedwithremdesivir AT deboermarkgj liverandkidneyfunctioninpatientswithcovid19treatedwithremdesivir AT gomberthandokokimb liverandkidneyfunctioninpatientswithcovid19treatedwithremdesivir AT guchelaarhenkjan liverandkidneyfunctioninpatientswithcovid19treatedwithremdesivir AT zwavelingjuliette liverandkidneyfunctioninpatientswithcovid19treatedwithremdesivir AT liverandkidneyfunctioninpatientswithcovid19treatedwithremdesivir |